港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

887.671

-2.413-0.27%

漲家數：4

跌家數：6

平家數：3

市盈率：- -

高：889.747

開：889.747

低：879.542

收：890.084

成交量：1,790.02萬

成交額：1.80億

市值：1,480.81億

流通市值：1,087.51億

資料載入中...

總覽新聞資訊

三生製藥(01530)出現大手買入47.45萬股，成交價$16.02，涉資760.149萬

阿斯达克财经

復星國際(00656.HK)：復星醫藥(02196.HK)減持印度注射劑藥品生產製造公司6%股權套現2.94億美元

阿斯达克财经

港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權

港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)

復星醫藥(02196.HK)擬回購不超過10億港元H股

復星醫藥：擬12個月內回購不超過10億港元H股

南方财经网

復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權

復鋭醫療科技(01696.HK)將於9月11日派發末期股息每股0.095港元

復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股

復星醫藥：復星高科技質押3.30億股用於償還債務

南方财经网

港股異動 | 時代天使(06699.HK)漲近5% 上半年海外業務實現扭虧為盈大摩看好公司海內外市場具強勁銷量動能

港股異動 | 時代天使(06699)漲近5% 上半年海外業務實現扭虧為盈大摩看好公司海內外市場具強勁銷量動能

智通财经网

港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

康哲藥業：德維康產品Lumirix獲國家藥監局批准，用於特應性皮炎治療（2026年9月2日）

麗豐控股(01125)：公眾持股量為14.76%

復星醫藥(02196.HK)：蘆沃美替尼片新增適應症獲註冊批准

復星醫藥(600196.SH)子公司蘆沃美替尼片新增適應症獲註冊批准

大行評級丨招銀國際：時代天使上半年業績勝預期，目標價升至114.21港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1593/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":887.67145,"timestamp":1789535903879,"preClose":890.084,"halted":0,"volume":17900180,"delay":0,"changeRate":-0.00271,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-2.412537,"latestTime":"09-16 13:18:38","open":889.7474,"high":889.7474,"low":879.5415,"amount":180238545,"amplitude":0.011466,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789546200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":1.136925,"peRate":10.390002,"turnoverRate":0.000897,"increases":4,"decrements":6,"flats":3,"marketCap":148080568928,"floatMarketCap":108751185120},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":889.7474,"amplitude":0.011466,"preClose":890.084,"low":879.5415,"pbRate":"1.136925","latestPrice":887.67145,"volume":17900180,"delay":0,"open":889.7474,"prevYearClose":1094.978,"prevWeekClose":869.902,"prevMonthClose":902.195,"prevQuarterClose":846.145,"fiveDayClose":916.041,"twentyDayClose":932.26,"sixtyDayClose":841.364,"secType":"PLATE","market":"HK","turnoverRate":0.000897,"peRate":10.390002,"marketCap":148080568928,"floatMarketCap":108751185120,"timestamp":1789535903879,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665966603","title":"三生製藥(01530)出現大手買入47.45萬股，成交價$16.02，涉資760.149萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2665966603","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665966603?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 11:14","pubTimestamp":1788750840,"startTime":"0","endTime":"0","summary":"[大手成交]三生制药(01530)在上午11:14出现大手买入，成交量为47.45万，成交价为港币$16.02，涉资760.149万。至目前为止，股价跌1.416%，今日最高价为$16.22，而最低价为$15.81，总成交量为529.133万股，总成交金额港币$8.464千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609074476/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609074476/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000165453.HKD","BK1161","BK1583","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665839583","title":"復星國際(00656.HK)：復星醫藥(02196.HK)減持印度注射劑藥品生產製造公司6%股權  套現2.94億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665839583","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665839583?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:03","pubTimestamp":1788746580,"startTime":"0","endTime":"0","summary":"复星国际公布，附属复星医药全资附属复星医药新加坡公司，通过大宗交易及集中竞价方式出售共计989.7万股Gland Pharma Limited股份，约占该公司股份总数的6%，出售事项的总代价约为279.96亿卢比。Gland Pharma Limited是一间根据印度法律成立的公司，其主要从事注射剂药品的生产制造业务，其股份于孟买证券交易所及印度国家证券交易所上市，股份代号：GLAND。于出售事项前及完成后，复星国际分别持有Gland Pharma约51.76%及45.76%的股权，该公司仍为复星医药及复星国际的附属。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220902164047308_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220902164047308_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543112/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543112/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1230","02196","BK0188","BK1515","BK0060","MNDmain","BK0183","00656","600196","BK0096","BK0175","BK0196","BK0187","BK1593","BK0239","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935403","title":"港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935403?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:35","pubTimestamp":1788744909,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","VTHR","VXUS","BK1161","BK1574","02196","IBBQ","03696","BK1617","BK1141","LNGR","BK1593","02228","MEDX","KCAI","159992","AIPO","BK1191","ARTY","AGIX","BK4585","BK1515","QTOC","CHAT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665517364","title":"復星醫藥(02196.HK)擬回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665517364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665517364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:25","pubTimestamp":1788690331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","BK1191","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364975","title":"復星醫藥：擬12個月內回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364975","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364975?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:12","pubTimestamp":1788689520,"startTime":"0","endTime":"0","summary":"南财智讯9月6日电，复星医药（02196.HK）发布自愿公告，基于对集团发展前景的信心及内在价值的认可，经董事会批准，公司拟自2026年8月27日起12个月内回购H股，回购资金总额不超过10亿港元。本次回购依据2026年6月16日股东周年大会、H股类别股东会及A股类别股东会授予董事会的H股回购一般性授权实施。回购H股用途包括注销或作为库存股份持有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609063866106963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609063866106963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0096","02196","BK0028","BK0060","BK0188","BK0183","BK0196","BK0012","BK1191","BK0187","600196","BK1593","BK0175","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361715","title":"復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361715?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 17:00","pubTimestamp":1788685207,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，印度时间2026年9月4日，公司控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售共计989.70万股 Gland Pharma 股份，交易总对价为279.96亿印度卢比，均价约为2,828.78印度卢比/股、较前一交易日收盘价格折让约2.72%。紧随本次交易完成后，集团仍持有 Gland Pharma 约45.76%的股权、为其控股股东，Gland Pharma 仍为集团合并报表范围内子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0187","BK1191","BK0188","600196","BK1593","BK0028","02196","BK0060","BK0012","BK0183","BK0096","BK0196","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331818","title":"復鋭醫療科技(01696.HK)將於9月11日派發末期股息每股0.095港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664331818?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 19:56","pubTimestamp":1788522961,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","01696","BK1100","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338732","title":"復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 17:26","pubTimestamp":1788513984,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03188","02196","02827","07233","BK1515","BK1191","02846","03130","82846","83188","BK1147","83130","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840380","title":"復星醫藥：復星高科技質押3.30億股用於償還債務","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840380","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664840380?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:25","pubTimestamp":1788510357,"startTime":"0","endTime":"0","summary":"南财智讯9月4日电，复星医药公告，公司控股股东上海复星高科技(集团)有限公司于2026年9月3日将其持有的330000000股A股股份办理质押，占其所持股份比例34.32%，占公司总股本比例12.36%，质押用途为偿还债务。本次质押后，复星高科技累计质押股份数量为696275000股，占公司总股本26.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865437383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0028","BK0183","BK0188","BK0012","BK0175","BK0096","BK1593","BK0060","BK1191","600196","BK1515","BK0196","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664384349","title":"港股異動 | 時代天使(06699.HK)漲近5% 上半年海外業務實現扭虧為盈 大摩看好公司海內外市場具強勁銷量動能","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664384349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:19","pubTimestamp":1788502744,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06699","BK1100","BK1593","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664384342","title":"港股異動 | 時代天使(06699)漲近5% 上半年海外業務實現扭虧為盈 大摩看好公司海內外市場具強勁銷量動能","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384342","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664384342?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:19","pubTimestamp":1788502744,"startTime":"0","endTime":"0","summary":"时代天使(06699)涨近5%，截至发稿，涨3.62%，报98.7港元，成交额6062.76万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260904/20260904142443_92018.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260904/20260904142443_92018.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131342.USD","IAI","IE00BKVL7J92.USD","LU0795875086.SGD","LU0971096721.USD","LU1363072403.SGD","LU1162221912.USD","IE00B775SV38.USD","LU0320765646.SGD","LU1074936037.SGD","LU0390134368.USD","BK1593","LU0528227936.USD","LU0234570918.USD","BK1587","LU0912757837.SGD","LU2133065610.SGD","LU2487616109.SGD","BK4534","LU1988902786.USD","BK4585","LU2089283258.USD","LU2264538146.SGD","LU0210528500.USD","LU1548497426.USD","LU0225283273.USD","KBWB","IE00BZ1G4Q59.USD","LU2028103732.USD","BK4588","BK4504","LU0098860793.USD","LU0882574139.USD","BK4516","VXUS","BK4127","LU1720051108.HKD","06699","LU2357305700.SGD","BK4581","BK1583","LU1720051017.SGD","KCAI","LU0053666078.USD","LU0006306889.USD","LU2111349929.HKD","LU0795875169.SGD","LU1791710582.SGD","LU2089284900.SGD","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386607","title":"港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386607?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","KCAI","BK1600","VXUS","BK1593","BK4588","02575","00460","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875311","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875311?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年9月2日获得中国国家药品监督管理局批准磷酸芦可替尼乳膏百卢妥轻中度特应性皮炎的新药上市许可申请，并于2026年九月3日获得药品注册证书。2026年1月，百卢妥中国NDA获批，成为中国批准的首款用于白癜风治疗的外用 JAK抑制剂。继百卢妥获批白癜风适应症后，此次AD适应症NDA获批，将进一步拓展产品的临床应用空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06978","IE00BYV24P56.USD","SG9999015945.SGD","SG9999015986.USD","MEDX","00867","BK1574","IE00BGHQDM52.EUR","SG9999004220.SGD","159992","IBBQ","IE00BVYPNP33.GBP","BK1161","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","SG9999015978.USD","AD","BK1593","BK1191","LNGR","LU2488822045.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664753128","title":"康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664753128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664753128?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","IE00BVYPNQ40.USD","SG9999015978.USD","BK1161","IE00BMCWC346.EUR","SG9999004220.SGD","IE00BYV24P56.USD","SG9999015986.USD","BK1574","IE00BGHQDM52.EUR","SG9999015952.SGD","BK1593","BK1191","LU2488822045.USD","IE00BVYPNP33.GBP","SG9999015945.SGD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177316058","title":"康哲藥業：德維康產品Lumirix獲國家藥監局批准，用於特應性皮炎治療（2026年9月2日）","url":"https://stock-news.laohu8.com/highlight/detail?id=1177316058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177316058?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:56","pubTimestamp":1788429369,"startTime":"0","endTime":"0","summary":"2026年9月2日，康哲药业旗下德维康所提交的Lumirix新药申请，已正式获得国家药品监督管理局的批准，该药物适应症为特应性皮炎。这一获批标志着该产品在相关治疗领域迈出关键一步，为临床提供了新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00867","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","SG9999015952.SGD","BK1191","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BYV24P56.USD","SG9999015945.SGD","SG9999015986.USD","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664634873","title":"麗豐控股(01125)：公眾持股量為14.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664634873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664634873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:41","pubTimestamp":1788428501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽丰控股(01125)发布公告，于本公布日期，公司之公众持股量为14.76%，仍低于上市规则规定公司全部已发行股本之25%须由公众人士持有之水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01125","BK1593","BK1240"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781028","title":"復星醫藥(02196.HK)：蘆沃美替尼片新增適應症獲註冊批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664781028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:22","pubTimestamp":1788427355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","02196","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664264827","title":"復星醫藥(600196.SH)子公司蘆沃美替尼片新增適應症獲註冊批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664264827","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664264827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:21","pubTimestamp":1788423715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司就芦沃美替尼片(商品名：复迈宁、项目代号：FCN-159)新增适应症的药品注册申请获国家药品监督管理局批准，本次获批的新适应症为用于伴有症状、无法手术的丛状神经纤维瘤(PN)的I型神经纤维瘤病(NF1)成人患者。该药品为集团自主研发的创新型小分子化学药物，为MEK1/2选择性抑制剂。本次新增适应症获批，可为中国境内相关罕见肿瘤患者提供新的治疗选择，并进一步增强该药品的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0187","BK1515","BK1593","BK0012","BK0096","BK0175","BK0239","BK0183","BK1191","BK0196","600196","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664213498","title":"大行評級丨招銀國際：時代天使上半年業績勝預期，目標價升至114.21港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664213498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664213498?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:12","pubTimestamp":1788415941,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06699","BK1583","BK1100","BK1587","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":69,"code":"91000000","status":"200"}]}}